Skip to Content
Merck
  • [Takotsubo cardiomyopathy: a novel beta-adrenergic blocker withdrawal syndrome].

[Takotsubo cardiomyopathy: a novel beta-adrenergic blocker withdrawal syndrome].

Orvosi hetilap (2013-02-12)
János Tomcsányi, Kinga Jávor, Hrisula Arabadzisz, András Zsoldos, Vince Wagner, Balázs Sármán
ABSTRACT

The authors describe two cases of takotsubo cardiomyopathy developing after an abrupt withdrawal of carvedilol and bisoprolol. Takotsubo or stress cardiomyopathy is characterized by acute and reversible cardiac dysfunction without coronary artery disease. It is triggered by acute emotional or physical stress, drugs or drug withdrawal. The immediate discontinuation of the long acting vasodilator beta-blocker, carvedilol has not yet been described to cause takotsubo cardiomyopathy. The authors recommend cautious withdrawal of beta-blockers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bisoprolol hemifumarate salt, ≥98% (HPLC), solid
Bisoprolol for system suitability, European Pharmacopoeia (EP) Reference Standard
Bisoprolol fumarate, European Pharmacopoeia (EP) Reference Standard
Bisoprolol for peak identification, European Pharmacopoeia (EP) Reference Standard